{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:10:12Z","timestamp":1765887012390},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1007\/s11899-007-0033-z","type":"journal-article","created":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T17:40:20Z","timestamp":1191260420000},"page":"242-248","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Management of advanced-stage peripheral T-cell lymphomas"],"prefix":"10.1007","volume":"2","author":[{"given":"Eva","family":"Kimby","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,10,2]]},"reference":[{"issue":"Suppl1","key":"33_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1023\/A:1008383406103","volume":"11","author":"N.L. Harris","year":"2000","unstructured":"Harris NL, Jaffe ES, Diebold J, et al.: Lymphoma classification\u2014from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms [review]. Ann Oncol 2000, 11(Suppl 1):3\u201310.","journal-title":"Ann Oncol"},{"key":"33_CR2","volume-title":"Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissue","year":"2001","unstructured":"Jaffe HN, Stein H (eds): Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissue. Lyon, France: IARC Press; 2001."},{"key":"33_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/sj.leu.2404481","volume":"21","author":"M. Bruggemann","year":"2007","unstructured":"Bruggemann M, White H, Gaulard P, et al.: Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies. Report of the BIOMED-2 Concerted Action BHM4 CT98-3936. Leukemia 2007, 21:215\u2013221.","journal-title":"Leukemia"},{"key":"33_CR4","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"M.A. Shipp","year":"1993","unstructured":"Shipp MA, Harrington DP, Anderson JR, et al.: A predictive model for aggressive NHL: The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329:987\u2013994.","journal-title":"N Engl J Med"},{"key":"33_CR5","first-page":"76","volume":"92","author":"C. Gisselbrecht","year":"1998","unstructured":"Gisselbrecht C, Gaulard P, Lepade E, et al.: Prognostic significance of T-cell phenotype in aggressive Non-Hodgkin\u2019s lymphomas. Blood 1998, 92:76\u201378.","journal-title":"Blood"},{"key":"33_CR6","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1365-2141.2005.05478.x","volume":"129","author":"R. Sonnen","year":"2005","unstructured":"Sonnen R, Schmidt W-P, Muller-Hermelink HK, Schmitz N: The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol 2005, 129:366\u2013372.","journal-title":"Br J Haematol"},{"key":"33_CR7","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/cncr.20999","volume":"103","author":"M.P. Escalon","year":"2005","unstructured":"Escalon MP, Liu NS, Yang Y, et al.: Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M.D. Anderson Cancer Center experience. Cancer 2005, 103:2091\u20132098.","journal-title":"Cancer"},{"key":"33_CR8","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A. Gallamini","year":"2004","unstructured":"Gallamini A, Stelitano C, Calvi R, et al.: Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004, 103:2474\u20132479.","journal-title":"Blood"},{"key":"33_CR9","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I","volume":"38","author":"E.M. McKelvey","year":"1976","unstructured":"McKelvey EM, Gottlieb JA, Wilson HE, et al.: Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976, 38:1484\u20131493.","journal-title":"Cancer"},{"key":"33_CR10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/annonc\/mdf033","volume":"13","author":"T. R\u00fcdiger","year":"2002","unstructured":"R\u00fcdiger T, Weisenburger DD, Anderson JR, et al.: Results from the Non-Hodgkin\u2019s Lymphoma Classification Project. Ann Oncol 2002, 13:140\u2013149.","journal-title":"Ann Oncol"},{"key":"33_CR11","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1182\/blood.V89.12.4514","volume":"89","author":"A. Melnyk","year":"1997","unstructured":"Melnyk A, Rodriguez A, Pugh WC, et al.: Evaluation of the Revised European-American Lymphoma Classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin\u2019s lymphoma. Blood 1997, 89:4514\u20134520.","journal-title":"Blood"},{"key":"33_CR12","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1023\/A:1008392528248","volume":"10","author":"M. Jerkeman","year":"1999","unstructured":"Jerkeman M, Anderson H, Cavallin-Stahl E, et al.: CHOP versus MACOP-B in aggressive lymphoma\u2014a Nordic Lymphoma Group randomised trial. Ann Oncol 1999, 10:1079\u20131086.","journal-title":"Ann Oncol"},{"issue":"suppl","key":"33_CR13","first-page":"591","volume":"22","author":"A. Delmer","year":"2003","unstructured":"Delmer A, Mounier N, Gaulard P, et al.: Intensified induction therapy with etoposide and high dose cytarabine in patients aged less than 60 years with peripheral T-cell and NK cell lymphoma. J Clin Oncol 2003, 22(suppl):591.","journal-title":"J Clin Oncol"},{"key":"33_CR14","doi-asserted-by":"crossref","unstructured":"Gressin R, Peoch M, Deconinck E, et al.: The VIP-ABVD regimen is not superior to the CHOP 21 for the treatment of non epidermotropic peripheral T cell lymphoma. Final results of the \u201cLTP95\u201d protocol of the GOELAMS [abstract]. Blood (ASH Annual Meeting Abstracts) 2006, 108:Abstract 2464.","DOI":"10.1182\/blood.V108.11.2464.2464"},{"key":"33_CR15","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","volume":"104","author":"M. Pfreundschuh","year":"2004","unstructured":"Pfreundschuh M, Truemper L, Kloess M, et al., and the German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004, 104:626\u2013633.","journal-title":"Blood"},{"key":"33_CR16","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","volume":"104","author":"M. Pfreundschuh","year":"2004","unstructured":"Pfreundschuh M, Truemper L, Kloess M, et al.: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004, 104:634\u2013641.","journal-title":"Blood"},{"issue":"Suppl2","key":"33_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1053\/j.seminhematol.2005.12.010","volume":"43","author":"R. Kurzrock","year":"2006","unstructured":"Kurzrock R, Ravandi F: Purine analogues in advanced T-cell lymphoid malignancies. Semin Hematol 2006, 43(Suppl 2):27\u201334","journal-title":"Semin Hematol"},{"key":"33_CR18","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1023\/A:1008409601731","volume":"9","author":"P.L. Zinzani","year":"1998","unstructured":"Zinzani PL, Magagnoli M, Bendandi M, et al.: Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 1998, 9:1351\u20131353.","journal-title":"Ann Oncol"},{"key":"33_CR19","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2001.19.17.3766","volume":"19","author":"J. Rodriguez","year":"2001","unstructured":"Rodriguez J, Munsell M, Yazji S, et al.: Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001, 19:3766\u20133770.","journal-title":"J Clin Oncol"},{"key":"33_CR20","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1046\/j.1365-2141.2003.04203.x","volume":"120","author":"K.W. Song","year":"2003","unstructured":"Song KW, Mollee P, Keating A, Crump M: Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 2003, 120:978\u2013985.","journal-title":"Br J Haematol"},{"key":"33_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/sj.bmt.1704367","volume":"33","author":"E. Jantunen","year":"2004","unstructured":"Jantunen E, Wiklund T, Juvonen E, et al.: Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant 2004, 33:405\u2013410.","journal-title":"Bone Marrow Transplant"},{"key":"33_CR22","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1365-2141.2006.06164.x","volume":"134","author":"T. Kewalramani","year":"2006","unstructured":"Kewalramani T, Zelenetz AD, Teruya-Feldstein J, et al.: Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 2006, 134:202\u2013207.","journal-title":"Br J Haematol"},{"key":"33_CR23","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/annonc\/mdl466","volume":"18","author":"J. Rodriguez","year":"2007","unstructured":"Rodriguez J, Conde E, Gutierrez A, et al.: The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007, 18:652\u2013657.","journal-title":"Ann Oncol"},{"key":"33_CR24","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/sj.thj.6200359","volume":"5","author":"P. Reimer","year":"2004","unstructured":"Reimer P, Schertlin T, R\u00fcdiger T, et al.: Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study. Hematol J 2004, 5:304\u2013311.","journal-title":"Hematol J"},{"key":"33_CR25","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","volume":"20","author":"P. Corradini","year":"2006","unstructured":"Corradini P, Tarella C, Zallio F, et al.: Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006, 20:1533\u20131538.","journal-title":"Leukemia"},{"key":"33_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","volume":"79","author":"J. Rodriguez","year":"2007","unstructured":"Rodriguez J, Conde E, Gutierrez A, et al.: Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 2007, 79:32\u201338.","journal-title":"Eur J Haematol"},{"key":"33_CR27","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","volume":"22","author":"P. Corradini","year":"2004","unstructured":"Corradini P, Dodero A, Zallio F, et al.: Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin\u2019s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004, 22:2172\u20132176.","journal-title":"J Clin Oncol"},{"key":"33_CR28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/sj.bmt.1705036","volume":"36","author":"G.G. Wulf","year":"2005","unstructured":"Wulf GG, Hasenkamp J, Jung W, et al.: Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin\u2019s lymphoma [letter]. Bone Marrow Transplant 2005, 36:271\u2013273.","journal-title":"Bone Marrow Transplant"},{"key":"33_CR29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B. Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235\u2013242.","journal-title":"N Engl J Med"},{"key":"33_CR30","doi-asserted-by":"crossref","unstructured":"Pfreundschuh M, Kloess M, Schmits R, et al.: Six, not eight cycles of bi-weekly CHOP with rituximab (R-CHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): results of the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 13.","DOI":"10.1182\/blood.V106.11.13.13"},{"key":"33_CR31","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/sj.thj.6200119","volume":"2","author":"E. Rossmann","year":"2001","unstructured":"Rossmann E, Lundin J, Lenkei R, et al.: Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J 2001, 2:300\u2013306.","journal-title":"Hematol J"},{"key":"33_CR32","doi-asserted-by":"publisher","first-page":"7174","DOI":"10.1158\/1078-0432.CCR-06-1275","volume":"12","author":"S.J. Rodig","year":"2006","unstructured":"Rodig SJ, Abramson JS, Pinkus GS, et al.: Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006, 12:7174\u20137192.","journal-title":"Clin Cancer Res"},{"key":"33_CR33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/10428190601016167","volume":"48","author":"S.T. Chang","year":"2007","unstructured":"Chang ST, Lu CL, Chuang SS, et al.: CD52 expression in non-mycotic T-and NK\/T-cell lymphomas. Leuk Lymphoma 2007, 48:117\u2013121.","journal-title":"Leuk Lymphoma"},{"key":"33_CR34","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","volume":"103","author":"G. Enblad","year":"2004","unstructured":"Enblad G, Hagberg H, Erlanson M, et al.: A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004, 103:2920\u20132924.","journal-title":"Blood"},{"key":"33_CR35","doi-asserted-by":"crossref","unstructured":"Trumper LH, Hohloch K, Kloess M, et al.: CHOP\/CHOEP-14 followed by consolidation with alemtuzumab in untreated aggressive T-cell lymphomas (DSHNHL 2003-1): feasibility and toxicity of a phase II trial of the German High Grade Non-Hodgkin\u2019s Lymphoma Group DSHNHL [abstract]. J Clin Oncol\n                           24(18S):7538.","DOI":"10.1200\/jco.2006.24.18_suppl.7538"},{"key":"33_CR36","doi-asserted-by":"crossref","unstructured":"Weidmann E, Hess G, Krause SW, et al.: Combination chemoimmunotherapy using alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) is an effective first-line regimen in peripheral T-cell lymphomas [abstract]. Blood (ASH Annual Meeting Abstracts) 2004, 104:Abstract 2640.","DOI":"10.1182\/blood.V104.11.2640.2640"},{"key":"33_CR37","doi-asserted-by":"crossref","unstructured":"Gallamini A, Zaja F, Patti C, et al.: Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL prospective multicenter trial. Blood 2007, In press.","DOI":"10.1182\/blood-2007-02-074641"},{"key":"33_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1586\/14737140.7.1.11","volume":"7","author":"F. Turturro","year":"2007","unstructured":"Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther 2007, 7:11\u201317.","journal-title":"Expert Rev Anticancer Ther"},{"key":"33_CR39","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/j.1365-2141.2006.06457.x","volume":"13","author":"N.H. Dang","year":"2007","unstructured":"Dang NH, Pro B, Hagemeister FB, et al.: Phase II trial of denileukin diftitox for relapsed\/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 2007, 13:439\u2013447.","journal-title":"Br J Haematol"},{"issue":"Suppl3","key":"33_CR40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1053\/j.seminoncol.2005.12.017","volume":"33","author":"F. Foss","year":"2006","unstructured":"Foss F: Clinical experience with denileukin diftitox (ONTAK). Semin Oncol 2006, 33(Suppl 3):11\u201316.","journal-title":"Semin Oncol"},{"key":"33_CR41","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1182\/blood-2006-12-062877","volume":"109","author":"Y.H. Kim","year":"2007","unstructured":"Kim YH, Duvic M, Obitz E, et al.: Clinical efficacy of zanolimumab (Hu Max-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007, 109:4655\u20134662.","journal-title":"Blood"},{"issue":"Suppl1","key":"33_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/sj.bjc.6603464","volume":"95","author":"O.A. O\u2019Connor","year":"2006","unstructured":"O\u2019Connor OA: Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma. Br J Cancer 2006, 95(Suppl 1):7\u201312.","journal-title":"Br J Cancer"},{"key":"33_CR43","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","volume":"25","author":"E.A. Olsen","year":"2007","unstructured":"Olsen EA, Kim YH, Kuzel TM, et al.: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007, 25:3109\u20133115.","journal-title":"J Clin Oncol"},{"key":"33_CR44","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/1042819031000077124","volume":"44","author":"E.S. Wang","year":"2003","unstructured":"Wang ES, O\u2019Connor O, She Y, et al.: Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 2003, 44:1027\u20131035.","journal-title":"Leuk Lymphoma"},{"key":"33_CR45","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/01.cco.0000245309.74767.20","volume":"18","author":"O.A. O\u2019Connor","year":"2006","unstructured":"O\u2019Connor OA: Pralatrexate: an emerging new agent with activity in T-cell lymphomas. Curr Opin Oncol 2006, 18:591\u2013597.","journal-title":"Curr Opin Oncol"},{"key":"33_CR46","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/blood-2005-03-1306","volume":"107","author":"M.A. Rizvi","year":"2006","unstructured":"Rizvi MA, Evens AM, Tallman MS, et al.: T-cell non-Hodgkin lymphoma [review]. Blood 2006, 107:1255\u20131264.","journal-title":"Blood"},{"key":"33_CR47","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1046\/j.1365-2141.2000.02098.x","volume":"109","author":"E. Deconinck","year":"2000","unstructured":"Deconinck E, Lamy T, Foussard C, et al.: Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial. Br J Haematol 2000, 109:736\u2013742.","journal-title":"Br J Haematol"},{"key":"33_CR48","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/blood.V93.11.3913","volume":"93","author":"R. Gascoyne","year":"1999","unstructured":"Gascoyne R, Aoun P, Wu D et al.: Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999, 93:3913\u20133921.","journal-title":"Blood"},{"key":"33_CR49","doi-asserted-by":"crossref","first-page":"364","DOI":"10.7326\/0003-4819-117-5-364","volume":"117","author":"W. Siegert","year":"1992","unstructured":"Siegert W, Agthe A, Griesser H, et al.: Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM\/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. Ann Intern Med 1992, 117:364\u2013370.","journal-title":"Ann Intern Med"},{"key":"33_CR50","first-page":"503","volume":"8","author":"N. Schmitz","year":"1991","unstructured":"Schmitz N, Prange E, Haferlach T, et al.: High-dose chemotherapy and autologous bone marrow transplantation in relapsing angioimmunoblastic lymphadenopathy with dysproteinemia (AILD). Bone Marrow Transplant 1991, 8:503\u2013550.","journal-title":"Bone Marrow Transplant"},{"key":"33_CR51","first-page":"1272","volume":"88","author":"J. Schetelig","year":"2003","unstructured":"Schetelig J, Fetscher S, Reichle A, et al.: Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 2003, 88:1272\u20131278.","journal-title":"Haematologica"},{"key":"33_CR52","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1600-0609.2007.00815.x","volume":"78","author":"J. Rodriguez","year":"2007","unstructured":"Rodriguez J, Conde E Gutierrez A: Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol 2007, 78:290\u2013296.","journal-title":"Eur J Haematol"},{"key":"33_CR53","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1080\/10428190601137658","volume":"48","author":"R. Advani","year":"2007","unstructured":"Advani R, Horwitz S, Zelenetz A, Horning SJ: Angio-immunoblastic T cell lymphoma: treatment experience with cyclosporine. Leuk Lymphoma 2007, 48:521\u2013525.","journal-title":"Leuk Lymphoma"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-007-0033-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-007-0033-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-007-0033-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-007-0033-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T10:00:24Z","timestamp":1659088824000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-007-0033-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["33"],"URL":"https:\/\/doi.org\/10.1007\/s11899-007-0033-z","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10]]},"assertion":[{"value":"2 October 2007","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}